Short-circuiting DCs in atherosclerosis

A team of European researchers has identified a way to target proinflammatory dendritic cells that contribute to atherosclerotic plaques in mice.¹ Carolus Therapeutics Inc. has a nonexclusive option to license the findings and believes the data may point to a new strategy for treating inflammation associated with cardiovascular and pulmonary disorders.

Multiple types of immune cells contribute to the proinflammatory pathology of atherosclerosis. Although macrophages are probably the best known cell type, other contributors include T cells and dendritic cells (DCs).²...